A randomized double blind placebo parallel controlled study on the effect of decoction of simiaoyongan on the paque fiber cap thickness in patients with carotid atherosclerosis

适应症

试验速览

阶段: 未知
状态: 招募中
发起方: Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

暂无简介。

•1. Patients with carotid atherosclerotic plaque diagnosed by color Doppler ultrasound;
•2. Patients with hs CRP >= 2mg / L;
•3. Patients aged between 40 and 80, regardless of gender;
•4. Patients who can take medicine for a long time;
•5. Patients who have informed consent shall sign the informed consent form.

•1. Patients with acute or subacute hemorrhage in plaque;
•2. Patients with complete calcification and fibrosis of plaque;
•3. MRI contraindications (such as pacemaker, denture, stent, etc.);
•4. Patients with active ulcer and bleeding tendency, long-term use of anticoagulant drugs (such as warfarin);
•5. Patients using dual antiplatelet drugs;
•6. Patients with severe arrhythmia, atrial fibrillation and heart failure;
•7. Patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system and respiratory system, whose liver function is more than 1.5 times higher than the upper limit of normal value, and Cr is higher than the normal value;
•8. Patients with any other life-threatening or serious diseases can not complete the 12-month treatment, so as to affect the evaluation results;
•9. Pregnant or lactating women, women with short-term pregnancy plans;
•10. Patients with allergic constitution;
•11. Patients with other diseases or psychosis that the researchers believe may limit the efficacy evaluation or follow-up of patients;
•12. Patients who have participated in clinical trials of other drugs in recent 4 weeks.

发起方